Sai Life Sciences shares debuted with a premium on NSE and BSE, exceeding market expectations. The IPO saw strong demand from institutional investors, while retail interest remained moderate. Experts advise allotted investors to consider booking profits above 15%, while long-term investors are encouraged to hold. The company plans to use the IPO proceeds for debt repayment and general corporate purposes.
